←
Locus Biosciences298 posts
Locus Biosciences avatar

Locus Biosciences

@LocusBio

Revolutionizing the treatment of bacterial disease.

◷ Joined May 2013▧ 62 Photos and videos
Locus Biosciences avatar
Locus Biosciences@LocusBio·10 Sep 2024

With #AntibioticResistance on the rise, Locus is pioneering a new approach using bacteriophages to combat infections and other diseases like #IBD. Our AI-designed phage therapy selectively targets harmful bacteria. Read more about our efforts in @WIRED. wired.com/story/crispr-enhan…

C&EN (Chemical & Engineering News) avatar
⟳ Locus Biosciences retweeted
C&EN (Chemical & Engineering News)@cenmag·7 Sep 2024

Largest ever phage therapy trial shows promise for UTI treatment Urinary tract–infecting E. coli are increasingly antibiotic resistant but phage therapy offers a compelling alternative: cen.acs.org/pharmaceuticals/… .

CRISPR Medicine avatar
⟳ Locus Biosciences retweeted
CRISPR Medicine@CrisprMedicine·21 Aug 2024

🫁 𝐂𝐑𝐈𝐒𝐏𝐑-𝐞𝐝𝐢𝐭𝐞𝐝 𝐩𝐡𝐚𝐠𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐞𝐥𝐢𝐦𝐢𝐧𝐚𝐭𝐞𝐬 𝐔𝐓𝐈 𝐢𝐧 𝐏𝐡𝐚𝐬𝐞 2 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥 🫁 US-based Locus Biosciences recently reported positive pharmacokinetic and safety data from the first part of the ongoing Phase 2 trial of CRISPR-edited phage therapy candidate LBP-EC01. LBP-EC01 is being developed as a novel treatment for uncomplicated urinary tract infections caused by drug-resistant E. coli. The data from the trial were published in The Lancet Infectious Diseases. Read our summary of the results here: crisprmedicinenews.com/news/… #crisprmedicinenews #crisprmedicine #crispr #phagetherapy #UTI #MDRbacteria #AMR #crisprtrial #clinicalnews #geneediting

Post attachment
NCBiotech avatar
⟳ Locus Biosciences retweeted
NCBiotech@ncbiotech·12 Aug 2024

NCBiotech portfolio company Locus Bio has announced positive results from the first portion of its Phase 2 trial in drug-resistant UTI, affecting an estimated 150 million people worldwide. Congratulations!

Positive results from Part 1 of our Phase 2 ELIMINATE trial evaluating genetically engineered bacteriophage therapy, LBP-EC01, to treat #UTIs were published in @TheLancet Infectious Diseases. Additionally, dosing has begun in Part 2 portion of this study. globenewswire.com/news-relea…

Post attachment
Locus Biosciences avatar
Locus Biosciences@LocusBio·26 Apr 2024

Excited to join the @ESCMID Global Conference & CARB-X Investor Day! 🌍 As pioneers in bacteriophage-based precision medicine, Locus looks forward to insightful discussions & collaborations driving innovation in combatting antibiotic resistance. #ESCMIDGlobal #CARBX #AMR